Infinity Holdings confirms no encumbrance of shares in Jagsonpal Pharmaceuticals for FY26
Infinity Holdings disclosed that it did not encumber any shares in Jagsonpal Pharmaceuticals Limited during FY26, as per SEBI Regulation 31(4). The declaration, dated April 06, 2026, confirms no direct or indirect pledging of shares by the promoter or persons acting in concert.

*this image is generated using AI for illustrative purposes only.
Infinity Holdings has confirmed that it did not create any encumbrance on its shares in Jagsonpal Pharmaceuticals Limited during the financial year ended March 31, 2026. The declaration, submitted on April 06, 2026, was made in accordance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation requires promoters to disclose any pledging or encumbrance of shares to ensure transparency for shareholders.
The disclosure covers both direct and indirect encumbrances. Infinity Holdings stated that no such activity was undertaken by it or by persons acting in concert with it throughout FY26. The filing was addressed to the Board of Directors and the Company Secretary of Jagsonpal Pharmaceuticals Limited , with copies sent to the Audit Committee and related entities such as Infinity Capital and Infinity Portfolio Holdings.
Regulatory Context
The filing is a mandatory compliance requirement under SEBI takeover regulations. It serves to inform the stock exchanges and the company's shareholders about the status of the promoter's holdings. A nil encumbrance status indicates that the promoter's shares are free from pledges, which is generally viewed as a positive indicator of corporate governance and financial stability.
Key Details of the Disclosure
| Detail | Information |
|---|---|
| Disclosing Entity | Infinity Holdings |
| Target Company | Jagsonpal Pharmaceuticals Limited |
| Regulation | SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Regulation 31(4) |
| Period Covered | Financial year ended March 31, 2026 |
| Encumbrance Status | None |
| Filing Date | April 06, 2026 |
The letter was signed by Ahmad Tariq Hossanee, Director of Infinity Holdings. The confirmation provides clarity to investors regarding the unencumbered status of the promoter's shareholding in the pharmaceutical company for the specified period.
Historical Stock Returns for Jagsonpal Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.20% | -3.55% | -4.17% | -6.56% | -13.18% | +284.57% |
Does Infinity Holdings plan to maintain this unencumbered status for the upcoming financial year?
How might this clean holding status influence Jagsonpal Pharmaceuticals' ability to secure future financing?
Could this signal a potential increase in promoter stake or a reduction in the same?


































